09:40 AM EDT, 08/29/2024 (MT Newswires) -- Adaptive Biotechnologies ( ADPT ) said Thursday that its clonoSEQ minimal residual disease test in lymphoid malignancies has received In Vitro Diagnostics Regulation class C certification in the European Union.

Under IVDR, the test is intended to detect minimal residual disease in patients with B-cell malignancies during and after treatment, the company said.

Shares of Adaptive Biotechnologies ( ADPT ) were up about 4% in early trading.

Price: 4.6900, Change: +0.18, Percent Change: +3.99